RT Journal Article
SR Electronic
T1 Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 693
OP 697
DO 10.3899/jrheum.191209
VO 48
IS 5
A1 Alexis Ogdie
A1 Mei Liu
A1 Meghan Glynn
A1 Kelechi Emeanuru
A1 Leslie R. Harrold
A1 Sven Richter
A1 Benoit Guerette
A1 Philip J. Mease
YR 2021
UL http://www.jrheum.org/content/48/5/693.abstract
AB Objective Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).Methods Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included.Results In total, 150 patients initiated monotherapy (apremilast: n = 34; MTX: n = 15; bDMARD: n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators.Conclusion Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA.